ACM
CALA

Atika Capital Management’s Calithera Biosciences, Inc CALA Stock Holding History

Atika Capital Management’s Portfolio CALA Stock Details CALA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q4 		– Sell
-11,730
Closed -$3.69M – 84
2017
Q3 		$3.69M Sell
11,730
-1,270
-10% -$401K 1.06% 33
2017
Q2 		$3.86M Buy
13,000
+400
+3% +$107K 1.35% 23
2017
Q1 		$2.91M Buy
+12,600
New +$2.18M 1.42% 30

Other funds holding CALA

Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
AC
Ascend Capital Orinda, California $1.99B AUM 10.36% 1-Year Est. Return

Atika Capital Management's CALA Position: Q4 2017 in Review

Atika Capital Management sold out of Calithera Biosciences, Inc (CALA) in Q4 2017, closing a stake of 11,730 shares — an estimated $3.69M sold.

Atika Capital Management first reported a position in CALA in Q1 2017 and held it in 3 quarters. The position peaked at $3.86M in Q2 2017. 112 funds tracked by Wall St. Rank hold CALA as of Q4 2017.

  • Atika Capital Management reported no remaining Calithera Biosciences, Inc position as of Q4 2017 after selling out during the quarter.
  • Atika Capital Management sold 11,730 Calithera Biosciences, Inc shares in Q4 2017, an estimated $3.69M.
  • Atika Capital Management first reported a position in Calithera Biosciences, Inc in Q1 2017 and held it in 3 quarters.
  • Atika Capital Management's Calithera Biosciences, Inc position peaked at $3.86M in Q2 2017.
  • 112 funds tracked by Wall St. Rank held Calithera Biosciences, Inc as of Q4 2017.

Based on Atika Capital Management's 13F filing for Q4 2017, filed 14 Feb 2018.